Study outcome won't sway company on eye drug (AP)
AP - What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?
Read More In: Staying in Touch
Stay up to date and advise your parents with the latest news about senior living and health in today's world.


RSS